Last reviewed · How we verify
Intralipid 20% I.V. Fat Emulsion
Intralipid is an intravenous fat emulsion that provides essential fatty acids and calories as a parenteral nutrition source.
Intralipid is an intravenous fat emulsion that provides essential fatty acids and calories as a parenteral nutrition source. Used for Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition, Prevention of essential fatty acid deficiency.
At a glance
| Generic name | Intralipid 20% I.V. Fat Emulsion |
|---|---|
| Sponsor | University of Michigan |
| Drug class | Parenteral lipid emulsion |
| Modality | Small molecule |
| Therapeutic area | Nutrition support |
| Phase | Phase 3 |
Mechanism of action
Intralipid 20% is a lipid emulsion composed of soybean oil, egg yolk phospholipids, glycerin, and water that delivers energy-dense nutrition intravenously. It supplies essential fatty acids (linoleic and alpha-linolenic acid) and calories to patients who cannot receive adequate nutrition orally or enterally. The emulsion is metabolized similarly to chylomicrons, providing both caloric support and prevention of essential fatty acid deficiency.
Approved indications
- Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition
- Prevention of essential fatty acid deficiency
Common side effects
- Hypertriglyceridemia
- Lipemia
- Thrombophlebitis at infusion site
- Allergic reactions
- Hepatomegaly
- Splenomegaly
Key clinical trials
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- Reversing Glucose and Lipid-mediated Vascular Dysfunction (EARLY_PHASE1)
- Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities (PHASE1)
- Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age (PHASE4)
- Impact of Plasma Lipids on β Cell Function and Insulin Sensitivity (NA)
- Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial (PHASE4)
- Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intralipid 20% I.V. Fat Emulsion CI brief — competitive landscape report
- Intralipid 20% I.V. Fat Emulsion updates RSS · CI watch RSS
- University of Michigan portfolio CI